The U.S. Food and Drug Administration (FDA) has approved the combined use of two powerful agents for the post-surgical treatment of renal cell carcinoma (RCC) patients at high risk of recurrence. This development opens the door to a new era in the treatment of early-stage kidney cancer.
June 13, 2026 — An exciting last-minute development took place in the world of oncology. As of June 12, 2026, the FDA officially approved a new combination as preventive (adjuvant) therapy for adult patients with clear cell renal cell carcinoma (ccRCC) who are at intermediate-high or high risk of recurrence following removal of the kidney (nephrectomy) or surgical removal of metastatic lesions.
According to the approved treatment protocol, belzutifan (Welireg), a HIF-2α inhibitor, may be used in combination with the immunotherapy drug pembrolizumab (Keytruda) or with pembrolizumab and berahyaluronidase alfa-pmph (Keytruda), the subcutaneous form of pembrolizumab.
The Study That Boosts the Chance of a Complete Cure: LITESPARK-022
This critical approval is based on the Phase 3 LITESPARK-022 clinical trial, conducted with 1,841 patients and whose results were presented at the ASCO Genitourinary Cancers Symposium, one of the leading events in the medical world.
Led by principal investigator Dr. Toni K. Choueiri of the Dana-Farber Cancer Institute, the study produced the following striking results:
- 28% Reduction in the Risk of Recurrence and Death: In patients receiving the belzutifan and pembrolizumab combination, the risk of cancer recurrence, metastasis or death was reduced by 28% compared with patients using pembrolizumab alone.
- 2-Year Cancer-Free Survival Rate: About 80% of treated patients remained completely cancer-free (disease-free survival – DFS) at 24 months, compared with 73% in the placebo/monotherapy group.
💬 What Do the Experts Say?
Commenting on the approval, the study's principal investigator Dr. Toni K. Choueiri stressed that surgery alone is not enough: "In many patients the disease unfortunately returns as metastatic after surgery. This new combination offers the most effective strategy we have to reduce the likelihood of the cancer coming back. This approval goes down in history as the first early-stage combination approval of PD-1 and HIF-2α inhibitors."
What Will the Dose and Administration Be?
According to the prescribing information published by the FDA, the recommended dosing guide is as follows:
| Drug / Form | Recommended Dose | Route and Duration |
|---|---|---|
| Belzutifan (Welireg) | 120 mg once daily | Oral Up to 54 weeks in the absence of recurrence or intolerable side effects. |
| Pembrolizumab (Keytruda) | 200 mg every 3 weeks or 400 mg every 6 weeks | Intravenous (IV) Up to 12 months. |
| Keytruda Qlex (subcutaneous form) | 395 mg/4,800 units every 3 weeks or 790 mg/9,600 units every 6 weeks | Subcutaneous Up to 12 months. |
Safety and Side-Effect Profile
The most common grade 3 and higher (serious) side effects observed with the combination therapy include:
- Anemia
- Elevated ALT (liver enzyme)
- Hypoxia (low oxygen)
Experts note that although the combination therapy increases the frequency of side effects compared with single agents, these effects are manageable and do not signal a new safety risk.
Conclusion
With this historic approval, belzutifan — following its success in advanced cancer treatment — has now taken a strong step into the early-stage, "cure-oriented" treatment arena. Industry officials announced that the full prescribing information will soon be available on the Drugs@FDA platform.